Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
St. Jude Children’s Research Hospital investigators prove that an immune marker predicts transplant success and improves selection of bone marrow donors (Dr. Wing Leung)
St. Jude research doesn’t stop when treatment ends. Studies conducted by our faculty and staff are uncovering new details about the long-term issues facing childhood cancer survivors.
St. Jude helps budding golfer Brennan Simkins through his battle with a rare form of acute myeloid leukemia, which required four bone marrow transplants.
St. Jude Children’s Research Hospital investigators reported markedly improved survival of pediatric patients transplanted for high-risk leukemia regardless of donor; cite treatment advances and better donor selection.
The first challenges surfaced in July 2007, when Jordan James was less than 2 days old. His mother Chancelly was recovering from a C-section delivery when Jordan, her only child, suffered a seizure. Within hours, both mother and child were in an ambulance speeding toward Memphis.
St. Jude Children’s Research Hospital investigators have identified childhood cancer survivors who are at increased risk for deteriorating lung health, in part due to the lifesaving bone marrow transplants they underwent years earlier.
Powerful but rare immune cells taken from a parent might provide a safe, effective and affordable approach to preventing cancer’s return in young patients with acute myeloid leukemia (AML), according to new St. Jude research.
Patient care at St. Jude doesn't stop when the child is cured. The end of successful therapy is the start of many years of follow-up care.
St. Jude clinicians used immune system cells called natural killer (NK) cells from a father to save the life of his 3-month-old infant daughter who wasn't expected to survive her battle with acute lymphoblastic leukemia (ALL).
St. Jude researchers have shown that it might be possible to significantly improve a commonly accepted technique used to identify the best donors of stem cells.